Table 2. Summary of response to treatment.
| Human PDAC Xenograft | Radio-therapy | Chemotherapy | Response to Treatment |
|---|---|---|---|
| 1 (OCIP23) | No | Gemcitabine* | Progression of disease |
| 2 (OCIP28) | Yes | Gemcitabine-Cisplatin# | Partial therapeutic response |
| Capecitabine* | No indication of disease | ||
| 3 (OCIP217) | Yes | Gemcitabine-Cisplatin# | Partial therapeutic response |
| Gemcitabine-Cisplatin+ | Stable disease | ||
| Carboplatin–paclitaxel | Progression of disease | ||
| 4 (OCIP167) | No | Gemcitabine* | No indication of disease |
| 5FU–irinotecan oxaliplatin+ | Stable disease | ||
| 5 (OCIP232) | No | Gemcitabine* | No indication of disease |
| 5FU–irinotecan–oxaliplatin–leucovorin+ | Initial therapeutic response but progressed after 6 months | ||
| Veliparib+ | Progression of disease |
Abbreviations: 5FU- 5-fluorouracil. Data has been adapted from Lohse et al. [85].
*
Adjuvant,
#
Neoadjuvant,
+
Palliative.